NEW THERAPEUTIC TARGET FOR THE TREATMENT OF MYOTONIC DYSTROPHY

Patent number:
Comunidad Valenciana.svg
No items found.

New target for use in the treatment of myotonic dystrophy. The treatment may be based on an oligonucleotide molecule and/or a small molecule that at least partially restores the phenotype of a patient with DM to a non-diseased state. Different molecules have been identified that produce such an effect.

Countries:
Spain
Regions:
Valencian Community
Centers:
UNIVERSITAT DE VALENCIA, FUNDACION INCLIVA
Other entities:
Sectors:
Health
Subsectors:
TRL Level:
TRL 3 – experimental proof of concept
BRL Level:
PDF Link:
Download here
Video Link:
Watch it here
Sustainable Development Goal:
SDG03: Good health and well-being
Applications

Applications; The main application of the technology is in the pharmaceutical sector, as an active ingredient for the treatment of Myotonic Dystrophy. Competitive advantages: The main advantages provided by the invention are: The identification of the target allows the selection of different drugs. The newly identified target is in the early stages of the pathogenesis pathway. Its reversion to the non-pathogenic state makes it possible that many characteristic phenotypes of the disease can be reversed or even prevented.

Comments

Other related patents

Health
Telecom

Methodology for the automated recognition of reptiles by transforming the markov model of the parametric fusion characteristics of their sound production.

Countries
Spain
Know more
Health

"Method to potentiate osteogenic differentiation of mesenchymal stromal cells (MSC)"

Countries
Spain
Know more
Health

REUSABLE NON-INVASIVE URINARY DEVICE FOR WOMEN IN SUPINE POSITION

Countries
Spain
Know more
Get back to patents directory